Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jonathan Wilson

Surgery Lees Summit, MO Doctor of Osteopathy

NPI 1649479916 CMS profile 210295

112 Nw Hackberry St, Lees Summit, MO 64064

Open in the dashboard

General payments

$21,313

208 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jonathan Wilson of Lees Summit, MO is reported in the CMS Open Payments database as having received $21,313 across 208 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,691 22
2024 General $2,168 25
2023 General $2,621 33
2022 General $2,892 38
2021 General $1,682 31
2020 General $5,210 31
2019 General $5,049 28

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jonathan Wilson
  • Surgery median
  • Middle half of Surgery
  • National median

In program year 2025, general payments to Jonathan Wilson were reported at $1,691. Among 17,702 Surgery profiles paid that year, the median was $280 and the middle half received between $91 and $1,259.

Show as a table
Year Jonathan Wilson Surgery median Middle half National median
2019 $5,049 $253 $82–$1,521 $163
2020 $5,210 $131 $40–$706 $114
2021 $1,682 $168 $50–$904 $132
2022 $2,892 $224 $76–$1,218 $149
2023 $2,621 $253 $82–$1,255 $160
2024 $2,168 $279 $90–$1,381 $164
2025 $1,691 $280 $91–$1,259 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Bard Peripheral Vascular, Inc. $7,618 47 payments
  2. Endologix, Inc. $5,394 36 payments
  3. W. L. Gore & Associates, Inc. $1,555 17 payments
  4. Medtronic, Inc. $1,542 23 payments
  5. AngioDynamics, Inc. $897 14 payments
  6. Silk Road Medical, Inc. $597 13 payments
  7. LeMaitre Vascular, Inc. $478 8 payments
  8. Inari Medical, Inc. $403 4 payments
  9. Organogenesis Inc. $331 4 payments
  10. Boston Scientific Corporation $280 3 payments
  11. Other $2,218 39 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $13,239 197 payments
  2. Consulting Fee $5,500 4 payments
  3. Travel and Lodging $2,574 7 payments
Products named General payments · program years 2019–2025
  1. CROSSER Peripheral Vascular $3,825 2 payments
  2. AFX $2,019 8 payments
  3. ENDURANT IIS $1,332 20 payments
  4. ENDOCROSS Device $906 4 payments
  5. Torus Stent Graft System $906 4 payments
  6. CROSSER BD Interventional - Peripheral Intervention $824 7 payments
  7. AURYON LASER SYSTEM 100-120 VAC $764 13 payments
  8. Alto Abdominal Stent Graft System $735 7 payments
  9. GORE VIABAHN VBX Balloon Expandable Endo $702 4 payments
  10. ENROUTE Transcarotid Stent $546 10 payments
  11. Other $8,282 137 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

154

Median for Vascular Surgery: 122

Drug cost

$1,066

Median for Vascular Surgery: $14,135

Branded share of claims

64.3%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clopidogrel Clopidogrel Bisulfate Brand 56 $646
Lidocaine-Prilocaine Lidocaine/Prilocaine Brand 25 $261
Cephalexin Generic 55 $128
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 18 $31

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 88 billing codes

Paid by Medicare

$170,355

Medicare's payments for the services billed

Medicare patients

358

Average age 74

Services billed

968

195 women, 163 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 51%
Ischemic heart disease 43%
Diabetes 41%
Chronic kidney disease 38%
Heart failure 30%
Atrial fibrillation 28%
Depression 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

208 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Surgery in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record